Loading...
Market
Will 23andMe be profitable by the end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
23andMe financial statements and earnings reports
Story
23andMe to Lay Off 200 Employees, Discontinue Therapeutics to Focus on Core Genetics Business
Nov 12, 2024, 12:41 AM
Genetic testing company 23andMe announced plans to lay off 40% of its workforce, or roughly 200 employees, incurring up to $12 million in one-time costs as part of a restructuring effort to streamline operations and reduce costs. The firm will discontinue its therapeutics division, effectively exiting the drug development business, to focus on its core consumer genetics offerings. The decision marks a significant shift for the company, which had previously embarked on drug discovery initiatives leveraging its vast genetic data.
View original story
Similar markets
Above 50% increase • 25%
10% to 50% increase • 25%
0% to 10% increase • 25%
Decrease • 25%
Stock increases by 10% or more • 25%
Stock remains within +/- 10% • 25%
Stock decreases by 10% or more • 25%
Stock remains volatile with no clear trend • 25%
Outperforms competitors • 25%
Matches competitors • 25%
Underperforms competitors • 25%
Significantly underperforms competitors • 25%
Below $0.50 • 25%
$0.50 - $0.99 • 25%
$1.00 - $1.49 • 25%
$1.50 and above • 25%
Outperforms NASDAQ • 25%
Performs on par with NASDAQ • 25%
Underperforms NASDAQ • 25%
Delisted from NASDAQ • 25%